Ammonia Drug Information
Generic name: NH3N13
Radioactive Diagnostic Agent [EPC]
Uses of Ammonia
Ammonia N 13 Injection is indicated for diagnostic Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. Ammonia N 13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.
Dosage & Administration of Ammonia
| Organ | Adult |
|---|---|
| Adrenals | 0.0085 |
| Bladder wall | 0.030 |
| Bone surfaces | 0.0059 |
| Brain | 0.016 |
| Breast | 0.0067 |
| Stomach wall | 0.0063 |
| Small intestine | 0.0067 |
| *ULI | 0.0067 |
| **LLI | 0.0070 |
| Heart | 0.0078 |
| Kidneys | 0.017 |
| Liver | 0.015 |
| Lungs | 0.0093 |
| Ovaries | 0.0063 |
| Pancreas | 0.0070 |
| Red marrow | 0.0063 |
| Spleen | 0.0093 |
| Testes | 0.0067 |
| Thyroid | 0.0063 |
| Uterus | 0.0070 |
| Other tissues | 0.0059 |
Side Effects of Ammonia
No adverse reactions have been reported for Ammonia N 13 Injection based on a review of the published literature, publicly available reference sources, and adverse drug reaction reporting systems. However, the completeness of these sources is not known. No adverse reactions have been reported for Ammonia N 13 Injection based on a review of the published literature, publicly available reference sources, and adverse drug reaction reporting system.
To report SUSPECTED ADVERSE REACTIONS, contact UCSF Radiopharmaceutical Facility at 1-415-353-4435 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Warnings & Cautions for Ammonia
Radiation Risks Ammonia N 13 Injection may increase the risk of cancer.
Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker .
Drug Interactions with Ammonia
The possibility of interactions of Ammonia N 13 Injection with other drugs taken by patients undergoing PET imaging has not been studied.
Clinical Studies of Ammonia
In a descriptive, prospective, blinded image interpretation study 2 of adult patients with known or suspected coronary artery disease, myocardial perfusion deficits in stress and rest PET images obtained with Ammonia N 13 (N=111) or Rubidium 82 (N=82) were compared to changes in stenosis flow reserve (SFR) as determined by coronary angiography. The principal outcome of the study was the evaluation of PET defect severity relative to SFR. PET perfusion defects at rest and stress for seven cardiac regions(anterior, apical, anteroseptal, posteroseptal, anterolateral, posterolateral, and inferior walls) were graded on a 0 to 5 scale defined as normal, possible, probable, mild, moderate, and severe defects. Coronary angiograms were used to measure absolute and relative stenosis dimensions and to calculate stenosis flow reserve defined as the maximum value of flow at maximum coronary vasodilatation relative to rest flow under standardized hemodynamic conditions.
SFR scores ranged from 0 (total occlusion) to 5 (normal). With increasing impairment of flow reserve, the subjective PET defect severity increased. A PET defect score of 2 or higher was positively correlated with flow reserve impairment (SFR<3).
Drug information sourced from the FDA. This content is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before making any medication decisions.
Ready to save on Ammonia?
Compare prescription prices at over 70,000 pharmacies and start saving today—no enrollment required.
Compare Ammonia Prices